Jankovic Joseph
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Mov Disord. 2017 Aug;32(8):1131-1138. doi: 10.1002/mds.27072. Epub 2017 Jun 22.
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions. In addition to onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and RimabotulinumtoxinB (Myobloc or NeuroBloc) there are other novel botulinun neurotoxin products currently in development. With a better understanding of the cellular mechanisms of botulinun neurotoxin and advances in biotechnology, future botulinun neurotoxin products will likely be even more effective and customized to the specific indication and tailored to the needs of the patients. © 2017 International Parkinson and Movement Disorder Society.
肉毒杆菌神经毒素（BoNT）已成为现代医学中用途最广泛的治疗药物之一，其临床应用比目前市场上的任何其他药物都要多。肉毒杆菌神经毒素最初用于治疗斜视和神经运动障碍，在过去30年中，其应用范围不断扩大，包括治疗各种眼科、胃肠道、泌尿科、骨科、皮肤科、牙科、分泌性、疼痛性、美容性及其他病症。除了A型肉毒毒素（保妥适）、A型肉毒毒素（得保松）、A型肉毒毒素（泽明）和B型肉毒毒素（迈保生或纽保生）外，目前还有其他新型肉毒杆菌神经毒素产品正在研发中。随着对肉毒杆菌神经毒素细胞机制的深入了解以及生物技术的进步，未来的肉毒杆菌神经毒素产品可能会更加有效，并针对特定适应症进行定制，以满足患者的需求。© 2017国际帕金森病和运动障碍协会。
